Tempus AI

Tempus AI, Inc. (NASDAQ: TEM) is a technology company leading the adoption of AI to advance precision medicine.

Founded 2015

Chicago, United States 3178 employees IPO Total: $2.75B AI, Biotechnology +2

General Information

Company Name Tempus AI

Founded Year 2015

Location

Chicago, United States

Employees 3178

Industries AI, Biotechnology, Health Care +1

Funding Stage IPO

Business Model B2B, B2B2C, Platform

Revenue Model Service Fee, Data Monetization, Licensing

Offices as of Oct 2026

Chicago, United States San Francisco, United States New York, United States Boston, United States Durham, United States Peachtree Corners, United States Barcelona, Spain

Social

BounceWatch is an independent company data service, not affiliated with Tempus AI. To contact Tempus AI, visit tempus.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Tempus AI compare?

A PDF of Tempus AI and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Tempus AI soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Tempus AI on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

United States Market

Market Signals All Companies

Industry Signals All Companies in United States

Tempus AI Alternatives

All Signals Trend Reports

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Feature Release Nov 05, 2026

Tempus AI launched new skills for Tempus One's knowledge layer to ground high-fidelity analyses in the data model and schema.

Event Participation Nov 04, 2026

Tempus AI is participating in the AMP2026 conference at Booth #909 to showcase its genomic testing and AI-powered pathology applications.

Certification Oct 26, 2026

Tempus AI's xR assay received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device.

In The News Oct 24, 2026

Featured on Seeking Alpha: How Tempus AI Built A Defensible Data Moat In Precision Healthcare

Revenue Metrics Oct 24, 2026

Tempus AI has secured data licensing agreements worth $192.5 million.

New Partnership Oct 19, 2026

Tempus AI has a collaboration with Pfizer, focusing on leveraging AI to analyze H&E pathology images for identifying advanced NSCLC patients who may need biomarker testing.

+2 more signals in last 30 days

Tempus AI a competitor of yours? Have our desk watch it

About Tempus AI

Tempus AI, Inc. (NASDAQ: TEM) is at the forefront of integrating artificial intelligence into the healthcare sector, emphasizing the power of precision medicine. Since its founding in 2015, Tempus has focused on building one of the largest libraries of multimodal medical data globally, ensuring that every patient's treatment is informed by the accumulated experience of those before them.

Headquartered in the United States, Tempus operates within a dynamic intersection of AI, Biotechnology, Health Care, and Machine Learning. Its AI-enabled systems are designed to empower physicians with personalized care capabilities while bolstering therapeutic discoveries and developments.

A recent influx of $300.00 million through a Post-IPO Debt investment on 19 February 2025, led by Ares Management, highlights the continued confidence in Tempus's innovative edge and market potential.

Business keywords: Precision Medicine, Multimodal Data, Clinical Data Interpretation, Molecular Data Analysis, Personalized Patient Care, Therapeutics Development, AI-Enabled Healthcare Solutions, Patient Data Utilization, Healthcare Operating Systems, Medical Data Libraries, Healthcare Innovation

Services & Products

AI-Enabled Healthcare Solutions

Diagnostic Tools Development

Healthcare Data Analytics

Research Program Partnerships

Target Customers

Healthcare Providers Research Institutions Medical Professionals Healthcare Researchers

Funding Rounds & Investors (17)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Convertible	$400.00M	-		01 May 2026
Post-IPO Equity	$520.00K	1	Ark Invest	01 Jan 2026
Post-IPO Equity	$8.80M	-		01 Sep 2025
Post IPO Convertible	$650.00M	-		01 Jun 2025
Post-IPO Debt	$300.00M	1	Ares Management	01 Feb 2025
IPO	$472.31M	-		01 Jun 2024
Debt Financing	$100.00M	-		01 Oct 2022
Series G	$200.00M	5	Novo Holdings, T. Rowe Price +3	01 Dec 2020
Series G	$100.00M	4	Novo Holdings, Baillie Gifford +2	01 Mar 2020
Series F	$200.00M	5	Novo Holdings, Revolution +3	01 May 2019

View All 17 Funding Rounds

Latest News

View All

Tempus AI enters data licensing agreements with BMS and Pathos AI worth $192.5 million

Investing.com Australia Oct 24, 2026

Tempus AI and Pathos AI Sign Neurology Data Deal Worth Up to $55 Million

Www.tokenpost.com Oct 24, 2026

How Tempus AI Built A Defensible Data Moat In Precision Healthcare

Seeking Alpha Oct 24, 2026

Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)?

Simply Wall Street Oct 03, 2026

Tempus AI Is Maintained at Buy by Guggenheim

Moomoo Oct 02, 2026

Recursion Pharmaceuticals (RXRX) Following Its Tempus AI Deal And The Valuation Debate

Simply Wall Street Oct 02, 2026

Tempus AI Alternatives & Competitors

View All Alternatives

Tempus AI vs

Massive Bio Turkey

AI-driven system connecting cancer patients to clinical trials in real time. Industrializing the onc...

Series B

103 employees

AI, Big Data

Tempus AI vs

ARTBIO United States

Channeling Energy. Changing Lives.

Series B

74 employees

Biotechnology, Health Care

Tempus AI vs

HEALWELL AI (TSX: AIDX) Canada

AI Accelerated Preventative Healthcare

Post-IPO Equity

476 employees

AI, Care Economy

View all alternatives

FAQ About Tempus AI

Tempus AI, Inc. (NASDAQ: TEM) is a technology company leading the adoption of AI to advance precision medicine.

Tempus AI was founded in 2015.

Tempus AI is headquartered in Chicago, United States. As of Oct 2026, it also has offices in San Francisco, United States, New York, United States, Boston, United States, Durham, United States and Peachtree Corners, United States.

Tempus AI operates in AI, Biotechnology, Health Care and Machine Learning. Its work centres on Precision Medicine, Multimodal Data, Clinical Data Interpretation and Molecular Data Analysis. Its customers include Healthcare Providers, Research Institutions and Medical Professionals.

Tempus AI has a B2B, B2B2C and Platform business model. Its revenue comes from Service Fee, Data Monetization and Licensing.

Tempus AI has approximately 3178 employees.

Tempus AI has completed 17 funding rounds, raising a total of $2.75B. The latest funding stage is IPO.

Tempus AI offers: AI-Enabled Healthcare Solutions, Diagnostic Tools Development, Healthcare Data Analytics, Research Program Partnerships.

Top alternatives and competitors to Tempus AI include Massive Bio, ARTBIO, HEALWELL AI (TSX: AIDX), Berlin Institute of Health in der Charité, OncoHost. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Tempus AI and Massive Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Tempus AI, https://bouncewatch.com/company/tempus-ai, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Tempus AI

General Information

Discover More

What changed at Tempus AI recently?

About Tempus AI

Services & Products

Target Customers

Funding Rounds & Investors (17)

Latest News

Tempus AI Alternatives & Competitors

FAQ About Tempus AI